AIM
LAB icon

Aigen Investment Management’s Standard BioTools LAB Stock Holding History

Aigen Investment Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,169
Closed -$28.4K – 667
2025
Q4 		$28.4K Buy
+22,169
New +$29.8K 0.01% 545
2022
Q1 		– Sell
-10,382
Closed -$43K – 835
2021
Q4 		$43K Buy
+10,382
New +$48.6K ﹤0.01% 1015

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Aigen Investment Management's LAB Position: Q1 2026 in Review

Aigen Investment Management sold out of Standard BioTools (LAB) in Q1 2026, closing a stake of 22,169 shares — an estimated $28.4K sold.

Aigen Investment Management first reported a position in LAB in Q4 2021 and held it in 2 quarters. The position peaked at $43K in Q4 2021. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Aigen Investment Management reported no remaining Standard BioTools position as of Q1 2026 after selling out during the quarter.
  • Aigen Investment Management sold 22,169 Standard BioTools shares in Q1 2026, an estimated $28.4K.
  • Aigen Investment Management first reported a position in Standard BioTools in Q4 2021 and held it in 2 quarters.
  • Aigen Investment Management's Standard BioTools position peaked at $43K in Q4 2021.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.